Epigenetic modulation as a therapeutic approach for pulmonary arterial hypertension

Experimental and Molecular Medicine

Volumn 47, Issue 7, 2015, Pages

  Kim, Jun Dae ^a   Lee, Aram ^b   Choi, Jihea ^b   Park, Youngsook ^b   Kang, Hyesoo ^b   Chang, Woochul ^c   Lee, Myeong Sok ^b   Kim, Jongmin ^b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Sookmyung Women's University   (South Korea)

^c Pusan National University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA;

ANIMAL; DNA METHYLATION; DRUG DEVELOPMENT; DRUG EFFECTS; GENE THERAPY; GENETIC EPIGENESIS; GENETICS; HUMAN; HYPERTENSION, PULMONARY; PROCEDURES;

ANIMALS; DNA METHYLATION; DRUG DISCOVERY; EPIGENESIS, GENETIC; GENETIC THERAPY; HUMANS; HYPERTENSION, PULMONARY; MICRORNAS;

EID: 84949838007     PISSN: 12263613     EISSN: 20926413     Source Type: Journal    
DOI: 10.1038/EMM.2015.45     Document Type: Review

References (121)

1. Kim J. Apelin-APJ signaling: a potential therapeutic target for pulmonary arterial hypertension. Mol Cell 2014; 37: 196–201.
2. Simonneau G, Gatzoulis MA, Adatia I, Celermajer D, Denton C, Ghofrani A et al. [Updated clinical classification of pulmonary hypertension]. Turk Kardiyol Dern Ars 2014; 42(Suppl 1): 45–54.
3. Ma L, Chung WK. The genetic basis of pulmonary arterial hypertension. Hum Genet 2014; 133: 471–479.
4. Rosanio S, Pelliccia F, Gaudio C, Greco C, Keylani AM, D'Agostino DC. Pulmonary arterial hypertension in adults: novel drugs and catheter ablation techniques show promise? Systematic review on pharmacotherapy and interventional strategies. Biomed Res Int 2014; 2014: 743868.
5. Benza RL, Miller DP, Barst RJ, Badesch DB, Frost AE, McGoon MD. An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL Registry. Chest 2012; 142: 448–456.
6. Tuder RM, Archer SL, Dorfmüller P, Erzurum SC, Guignabert C, Michelakis E et al. Relevant issues in the pathology and pathobiology of pulmonary hypertension. J Am Coll Cardiol 2013; 62(25 Suppl): D4–D12.
7. Zhao L, Chen CN, Hajji N, Oliver E, Cotroneo E, Wharton J et al. Histone deacetylation inhibition in pulmonary hypertension: therapeutic potential of valproic acid and suberoylanilide hydroxamic acid. Circulation 2012; 126: 455–467.
8. Archer SL, Marsboom G, Kim GH, Zhang HJ, Toth PT, Svensson EC et al. Epigenetic attenuation of mitochondrial superoxide dismutase 2 in pulmonary arterial hypertension: a basis for excessive cell proliferation and a new therapeutic target. Circulation 2010; 121: 2661–2671.
9. Kim J, Hwangbo C, Hu X, Kang Y, Papangeli I, Mehrotra D et al. Restoration of impaired endothelial myocyte enhancer factor 2 function rescues pulmonary arterial hypertension. Circulation 2015; 131: 190–199.
10. Saco TV, Parthasarathy PT, Cho Y, Lockey RF, Kolliputi N. Role of epigenetics in pulmonary hypertension. Am J Physiol Cell Physiol 2014; 306: C1101–C1105.
11. Kim GH, Ryan JJ, Marsboom G, Archer SL. Epigenetic mechanisms of pulmonary hypertension. Pulm Circ 2011; 1: 347–356.
12. Movassagh M, Vujic A, Foo R. Genome-wide DNA methylation in human heart failure. Epigenomics 2011; 3: 103–109.
13. Liyanage VR, Jarmasz JS, Murugeshan N, Del Bigio MR, Rastegar M, Davie JR. DNA modifications: function and applications in normal and disease states. Biology (Basel) 2014; 3: 670–723.
14. Wu H, Zhang Y. Reversing DNA methylation: mechanisms, genomics, and biological functions. Cell 2014; 156: 45–68.
15. Kass SU, Pruss D, Wolffe AP. How does DNA methylation repress transcription? Trends Genet 1997; 13: 444–449.
16. Piccolo FM, Fisher AG. Getting rid of DNA methylation. Trends Cell Biol 2014; 24: 136–143.
17. De Carvalho DD, Sharma S, You JS, Su SF, Taberlay PC, Kelly TK et al. DNA methylation screening identifies driver epigenetic events of cancer cell survival. Cancer Cell 2012; 21: 655–667.
18. Stirzaker C, Taberlay PC, Statham AL, Clark SJ. Mining cancer methylomes: prospects and challenges. Trends Genet 2014; 30: 75–84.
19. Beck S, Rakyan VK. The methylome: approaches for global DNA methylation profiling. Trends Genet 2008; 24: 231–237.
20. Kalish JM, Jiang C, Bartolomei MS. Epigenetics and imprinting in human disease. Int J Dev Biol 2014; 58: 291–298.
21. Ho SM, Johnson A, Tarapore P, Janakiram V, Zhang X, Leung YK. Environmental epigenetics and its implication on disease risk and health outcomes. ILAR J 2012; 53: 289–305.
22. Talikka M, Sierro N, Ivanov NV, Chaudhary N, Peck MJ, Hoeng J et al. Genomic impact of cigarette smoke, with application to three smokingrelated diseases. Crit Rev Toxicol 2012; 42: 877–889.
23. Cheung P, Allis CD, Sassone-Corsi P. Signaling to chromatin through histone modifications. Cell 2000; 103: 263–271.
24. Zhou VW, Goren A, Bernstein BE. Charting histone modifications and the functional organization of mammalian genomes. Nat Rev Genet 2011; 12: 7–18.
25. Kouzarides T. Chromatin modifications and their function. Cell 2007; 128: 693–705.
26. Bannister AJ, Kouzarides T. Regulation of chromatin by histone modifications. Cell Res 2011; 21: 381–395.
27. Bhaumik SR, Smith E, Shilatifard A. Covalent modifications of histones during development and disease pathogenesis. Nat Struct Mol Biol 2007; 14: 1008–1016.
28. Bannister AJ, Schneider R, Kouzarides T. Histone methylation: dynamic or static? Cell 2002; 109: 801–806.
29. Greer EL, Shi Y. Histone methylation: a dynamic mark in health, disease and inheritance. Nat Rev Genet 2012; 13: 343–357.
30. Chen T, Dent SY. Chromatin modifiers and remodellers: regulators of cellular differentiation. Nat Rev Genet 2014; 15: 93–106.
31. Narlikar GJ, Sundaramoorthy R, Owen-Hughes T. Mechanisms and functions of ATP-dependent chromatin-remodeling enzymes. Cell 2013; 154: 490–503.
32. Arrowsmith CH, Bountra C, Fish PV, Lee K, Schapira M. Epigenetic protein families: a new frontier for drug discovery. Nat Rev Drug Discov 2012; 11: 384–400.
33. El Chami H, Hassoun PM. Immune and inflammatory mechanisms in pulmonary arterial hypertension. Prog Cardiovasc Dis 2012; 55: 218–228.
34. Oudhoff MJ, Freeman SA, Couzens AL, Antignano F, Kuznetsova E, Min PH et al. Control of the hippo pathway by Set7-dependent methylation of Yap. Dev Cell 2013; 26: 188–194.
35. Lee A, McLean D, Choi J, Kang H, Chang W, Kim J. Therapeutic implications of microRNAs in pulmonary arterial hypertension. BMB Rep 2014; 47: 311–317.
36. Wang D, Zhang H, Li M, Frid MG, Flockton AR, McKeon BA et al. MicroRNA-124 controls the proliferative, migratory, and inflammatory phenotype of pulmonary vascular fibroblasts. Circ Res 2014; 114: 67–78.
37. Faraci FM, Didion SP. Vascular protection: superoxide dismutase isoforms in the vessel wall. Arterioscler Thromb Vasc Biol 2004; 24: 1367–1373.
38. Kamezaki F, Tasaki H, Yamashita K, Tsutsui M, Koide S, Nakata S et al. Gene transfer of extracellular superoxide dismutase ameliorates pulmonary hypertension in rats. Am J Respir Crit Care Med 2008; 177: 219–226.
39. De Val S, Anderson JP, Heidt AB, Khiem D, Xu SM, Black BL. Mef2c is activated directly by Ets transcription factors through an evolutionarily conserved endothelial cell-specific enhancer. Dev Biol 2004; 275: 424–434.
40. Subramanian SV, Nadal-Ginard B. Early expression of the different isoforms of the myocyte enhancer factor-2 (MEF2) protein in myogenic as well as non-myogenic cell lineages during mouse embryogenesis. Mech Dev 1996; 57: 103–112.
41. Xu Z, Gong J, Maiti D, Vong L, Wu L, Schwarz JJ et al. MEF2C ablation in endothelial cells reduces retinal vessel loss and suppresses pathologic retinal neovascularization in oxygen-induced retinopathy. Am J Pathol 2012; 180: 2548–2560.
42. Kang Y, Kim J, Anderson JP, Wu J, Gleim SR, Kundu RK et al. Apelin-APJ signaling is a critical regulator of endothelial MEF2 activation in cardiovascular development. Circ Res 2013; 113: 22–31.
43. Kim J, Kang Y, Kojima Y, Lighthouse JK, Hu X, Aldred MA et al. An endothelial apelin-FGF link mediated by miR-424 and miR-503 is disrupted in pulmonary arterial hypertension. Nat Med 2013; 19: 74–82.
44. Goto Y, Shinjo K, Kondo Y, Shen L, Toyota M, Suzuki H et al. Epigenetic profiles distinguish malignant pleural mesothelioma from lung adenocarcinoma. Cancer Res 2009; 69: 9073–9082.
45. McLean DL, Kim J, Kang Y, Shi H, Atkins GB, Jain MK et al. Apelin/APJ signaling is a critical regulator of statin effects in vascular endothelial cells–brief report. Arterioscler Thromb Vasc Biol 2012; 32: 2640–2643.
46. Chandra SM, Razavi H, Kim J, Agrawal R, Kundu RK, de Jesus Perez V et al. Disruption of the apelin-APJ system worsens hypoxia-induced pulmonary hypertension. Arterioscler Thromb Vasc Biol 2011; 31: 814–820.
47. Ehrlich M, Horbelt D, Marom B, Knaus P, Henis YI. Homomeric and heteromeric complexes among TGF-β and BMP receptors and their roles in signaling. Cell Signal 2011; 23: 1424–1432.
48. Kawabata M, Imamura T, Miyazono K. Signal transduction by bone morphogenetic proteins. Cytokine Growth Factor Rev 1998; 9: 49–61.
49. Kim JD, Kang H, Larrivée B, Lee MY, Mettlen M, Schmid SL et al. Context-dependent proangiogenic function of bone morphogenetic protein signaling is mediated by disabled homolog 2. Dev Cell 2012; 23: 441–448.
50. Wiley DM, Kim JD, Hao J, Hong CC, Bautch VL, Jin SW. Distinct signalling pathways regulate sprouting angiogenesis from the dorsal aorta and the axial vein. Nat Cell Biol 2011; 13: 686–692.
51. Kim JD, Lee HW, Jin SW. Diversity is in my veins: role of bone morphogenetic protein signaling during venous morphogenesis in zebrafish illustrates the heterogeneity within endothelial cells. Arterioscler Thromb Vasc Biol 2014; 34: 1838–1845.
52. David L, Feige JJ, Bailly S. Emerging role of bone morphogenetic proteins in angiogenesis. Cytokine Growth Factor Rev 2009; 20: 203–212.
53. Morse JH, Jones AC, Barst RJ, Hodge SE, Wilhelmsen KC, Nygaard TG. Mapping of familial primary pulmonary hypertension locus (PPH1) to chromosome 2q31-q32. Circulation 1997; 95: 2603–2606.
54. Nichols WC, Koller DL, Slovis B, Foroud T, Terry VH, Arnold ND et al. Localization of the gene for familial primary pulmonary hypertension to chromosome 2q31-32. Nat Genet 1997; 15: 277–280.
55. Morse JH, Deng Z, Knowles JA. Genetic aspects of pulmonary arterial hypertension. Ann Med 2001; 33: 596–603.
56. Chida A, Shintani M, Nakayama T, Furutani Y, Hayama E, Inai K et al. Missense mutations of the BMPR1B (ALK6) gene in childhood idiopathic pulmonary arterial hypertension. Circ J 2012; 76: 1501–1508.
57. Du L, Sullivan CC, Chu D, Cho AJ, Kido M, Wolf PL et al. Signaling molecules in nonfamilial pulmonary hypertension. N Engl J Med 2003; 348: 500–509.
58. Garrido-Martin EM, Blanco FJ, Fernandez L A, Langa C, Vary CP, Lee UE et al. Characterization of the human activin-A receptor type II-like kinase 1 (ACVRL1) promoter and its regulation by Sp1. BMC Mol Biol 2010; 11: 51.
59. Guo M, Jiang Z, Zhang X, Lu D, Ha AD, Sun J et al. miR-656 inhibits glioma tumorigenesis through repression of BMPR1A. Carcinogenesis 2014; 35: 1698–1706.
60. Lee J, Son MJ, Woolard K, Donin NM, Li A, Cheng CH et al. Epigeneticmediated dysfunction of the bone morphogenetic protein pathway inhibits differentiation of glioblastoma-initiating cells. Cancer Cell 2008; 13: 69–80.
61. Liu D, Morrell NW. Genetics and the molecular pathogenesis of pulmonary arterial hypertension. Curr Hypertens Rep 2013; 15: 632–637.
62. Loyd JE. Pulmonary arterial hypertension: insights from genetic studies. Proc Am Thorac Soc 2011; 8: 154–157.
63. Austin ED, Loyd JE. The genetics of pulmonary arterial hypertension. Circ Res 2014; 115: 189–202.
64. Brock M, Trenkmann M, Gay RE, Michel BA, Gay S, Fischler M et al. Interleukin-6 modulates the expression of the bone morphogenic protein receptor type II through a novel STAT3-microRNA cluster 17/92 pathway. Circ Res 2009; 104: 1184–1191.
65. Brock M, Samillan VJ, Trenkmann M, Schwarzwald C, Ulrich S, Gay RE et al. AntagomiR directed against miR-20a restores functional BMPR2 signalling and prevents vascular remodelling in hypoxia-induced pulmonary hypertension. Eur Heart J 2014; 35: 3203–3211.
66. Wang Y, Kahaleh B. Epigenetic repression of bone morphogenetic protein receptor II expression in scleroderma. J Cell Mol Med 2013; 17: 1291–1299.
67. ten Dijke P, Goumans MJ, Pardali E. Endoglin in angiogenesis and vascular diseases. Angiogenesis 2008; 11: 79–89.
68. Jin Z, Zhao Z, Cheng Y, Dong M, Zhang X, Wang L et al. Endoglin promoter hypermethylation identifies a field defect in human primary esophageal cancer. Cancer 2013; 119: 3604–3609.
69. Wang BW, Wu GJ, Cheng WP, Shyu KG. MicroRNA-208a increases myocardial fibrosis via endoglin in volume overloading heart. PLoS ONE 2014; 9: e84188.
70. Chen XP, Chen YG, Lan JY, Shen ZJ. MicroRNA-370 suppresses proliferation and promotes endometrioid ovarian cancer chemosensitivity to cDDP by negatively regulating ENG. Cancer Lett 2014; 353: 201–210.
71. Nasim MT, Ogo T, Ahmed M, Randall R, Chowdhury HM, Snape KM et al. Molecular genetic characterization of SMAD signaling molecules in pulmonary arterial hypertension. Hum Mutat 2011; 32: 1385–1389.
72. Shintani M, Yagi H, Nakayama T, Saji T, Matsuoka R. A new nonsense mutation of SMAD8 associated with pulmonary arterial hypertension. J Med Genet 2009; 46: 331–337.
73. Kato RB, Roy B, De Oliveira FS, Ferraz EP, De Oliveira PT, Kemper AG et al. Nanotopography directs mesenchymal stem cells to osteoblast lineage through regulation of microRNA-SMAD-BMP-2 circuit. J Cell Physiol 2014; 229: 1690–1696.
74. Nigam V, Sievers HH, Jensen BC, Sier HA, Simpson PC, Srivastava D et al. Altered microRNAs in bicuspid aortic valve: a comparison between stenotic and insufficient valves. J Heart Valve Dis 2010; 19: 459–465.
75. Tabruyn SP, Hansen S, Ojeda-Fernández ML, Bovy N, Zarrabeitia R, Recio-Poveda L et al. MiR-205 is downregulated in hereditary hemorrhagic telangiectasia and impairs TGF-beta signaling pathways in endothelial cells. Angiogenesis 2013; 16: 877–887.
76. Liang H, Xu C, Pan Z, Zhang Y, Xu Z, Chen Y et al. The antifibrotic effects and mechanisms of microRNA-26a action in idiopathic pulmonary fibrosis. Mol Ther 2014; 22: 1122–1133.
77. Rai D, Kim SW, McKeller MR, Dahia PL, Aguiar RC. Targeting of SMAD5 links microRNA-155 to the TGF-beta pathway and lymphomagenesis. Proc Natl Acad Sci USA 2010; 107: 3111–3116.
78. Liu Y, Sun R, Lin X, Liang D, Deng Q, Lan K. Kaposi’s sarcoma-associated herpesvirus-encoded microRNA miR-K12-11 attenuates transforming growth factor beta signaling through suppression of SMAD5. J Virol 2012; 86: 1372–1381.
79. Kim J, Ahn S, Ko YG, Boo YC, Chi SG, Ni CW et al. X-linked inhibitor of apoptosis protein controls alpha5-integrin-mediated cell adhesion and migration. Am J Physiol Heart Circ Physiol 2010; 299: H300–H309.
80. Mineo C, Shaul PW. Regulation of eNOS in caveolae. Adv Exp Med Biol 2012; 729: 51–62.
81. Hartung A, Bitton-Worms K, Rechtman MM, Wenzel V, Boergermann JH, Hassel S et al. Different routes of bone morphogenic protein (BMP) receptor endocytosis influence BMP signaling. Mol Cell Biol 2006; 26: 7791–7805.
82. Palacios-Ortega S, Varela-Guruceaga M, Milagro FI, Martínez JA, de Miguel C. Expression of Caveolin 1 is enhanced by DNA demethylation during adipocyte differentiation. status of insulin signaling. PLoS ONE 2014; 9: e95100.
83. Nohata N, Hanazawa T, Kikkawa N, Mutallip M, Fujimura L, Yoshino H et al. Caveolin-1 mediates tumor cell migration and invasion and its regulation by miR-133a in head and neck squamous cell carcinoma. Int J Oncol 2011; 38: 209–217.
84. Lin DH, Yue P, Pan C, Sun P, Wang WH. MicroRNA 802 stimulates ROMK channels by suppressing caveolin-1. J Am Soc Nephrol 2011; 22: 1087–1098.
85. Zhang Y, Qu X, Li C, Fan Y, Che X, Wang X et al. miR-103/107 modulates multidrug resistance in human gastric carcinoma by downregulating Cav-1. Tumour Biol 2014; 36: 2277–2285.
86. Lino Cardenas CL, Henaoui IS, Courcot E, Roderburg C, Cauffiez C, Aubert S et al. miR-199a-5p Is upregulated during fibrogenic response to tissue injury and mediates TGFbeta-induced lung fibroblast activation by targeting caveolin-1. PLoS Genet 2013; 9: e1003291.
87. Ørom UA, Lim MK, Savage JE, Jin L, Saleh AD, Lisanti MP et al. MicroRNA-203 regulates caveolin-1 in breast tissue during caloric restriction. Cell Cycle 2012; 11: 1291–1295.
88. Chung WK, Sampson KS, Kass RS. A novel channelopathy in pulmonary arterial hypertension. N Engl J Med 2013; 369: 2162.
89. Girerd B, Perros F, Antigny F, Humbert M, Montani D. KCNK3: new gene target for pulmonary hypertension? Expert Rev Respir Med 2014; 8: 385–387.
90. Latus H, Delhaas T, Schranz D, Apitz C. Treatment of pulmonary arterial hypertension in children. Nat Rev Cardiol 2015; 12: 244–254.
91. Zamanian RT, Kudelko KT, Sung YK, de Jesus Perez V, Liu J, Spiekerkoetter E. Current clinical management of pulmonary arterial hypertension. Circ Res 2014; 115: 131–147.
92. Chester AH, Yacoub MH. The role of endothelin-1 in pulmonary arterial hypertension. Glob Cardiol Sci Pract 2014; 2014: 62–78.
93. Miyagawa K, Emoto N. Current state of endothelin receptor antagonism in hypertension and pulmonary hypertension. Ther Adv Cardiovasc Dis 2014; 8: 202–216.
94. Lai YC, Potoka KC, Champion HC, Mora AL, Gladwin MT. Pulmonary arterial hypertension: the clinical syndrome. Circ Res 2014; 115: 115–130.
95. Das A, Durrant D, Salloum FN, Xi L, Kukreja RC. PDE5 inhibitors as therapeutics for heart disease, diabetes and cancer. Pharmacol Ther 2015; 147C: 12–21.
96. Pabani S, Mousa SA.. Current and future treatment of pulmonary hypertension. Drugs Today (Barc) 2012; 48: 133–147.
97. Chrysant SG. Effectiveness and safety of phosphodiesterase 5 inhibitors in patients with cardiovascular disease and hypertension. Curr Hypertens Rep 2013; 15: 475–483.
98. Montani D, Chaumais MC, Guignabert C, Günther S, Girerd B, Jaïs X et al. Targeted therapies in pulmonary arterial hypertension. Pharmacol Ther 2014; 141: 172–191.
99. Tu L, Guignabert C. Emerging molecular targets for anti-proliferative strategies in pulmonary arterial hypertension. Handb Exp Pharmacol 2013; 218: 409–436.
100. Cavasin MA, Demos-Davies K, Horn TR, Walker LA, Lemon DD, Birdsey N et al. Selective class I histone deacetylase inhibition suppresses hypoxia-induced cardiopulmonary remodeling through an antiproliferative mechanism. Circ Res 2012; 110: 739–748.
101. Bogaard HJ, Mizuno S, Hussaini AA, Toldo S, Abbate A, Kraskauskas D et al. Suppression of histone deacetylases worsens right ventricular dysfunction after pulmonary artery banding in rats. Am J Respir Crit Care Med 2011; 183: 1402–1410.
102. Esteller M, Fraga MF, Paz MF, Campo E, Colomer D, Novo FJ et al. Cancer epigenetics and methylation. Science 2002; 297: 1807–1808 discussion-8.
103. Schleithoff C, Voelter-Mahlknecht S, Dahmke IN, Mahlknecht U. On the epigenetics of vascular regulation and disease. Clin Epigenetics 2012; 4: 7.
104. Brock M, Haider TJ, Vogel J, Gassmann M, Speich R, Trenkmann M et al. The hypoxia-induced microRNA-130a controls pulmonary smooth muscle cell proliferation by directly targeting CDKN1A. Int J Biochem Cell Biol 2015; 61: 129–137.
105. Chen T, Zhou G, Zhou Q, Tang H, Ibe JC, Cheng H et al. Loss of microRNA-17 ∼ 92 in smooth muscle cells attenuates experimental pulmonary hypertension via induction of PDZ and LIM domain 5. Am J Respir Crit Care Med 2015; 191: 678–692.
106. Pullamsetti SS, Doebele C, Fischer A, Savai R, Kojonazarov B, Dahal BK et al. Inhibition of microRNA-17 improves lung and heart function in experimental pulmonary hypertension. Am J Respir Crit Care Med 2012; 185: 409–419.
107. Bertero T, Cottrill K, Krauszman A, Lu Y, Annis S, Hale A et al. The microRNA-130/301 family controls vasoconstriction in pulmonary hypertension. J Biol Chem 2015; 290: 2069–2085.
108. Bertero T, Lu Y, Annis S, Hale A, Bhat B, Saggar R et al. Systems-level regulation of microRNA networks by miR-130/301 promotes pulmonary hypertension. J Clin Invest 2014; 124: 3514–3528.
109. Jin Y, Pang T, Nelin LD, Wang W, Wang Y, Yan J et al. MKP-1 is a target of miR-210 and mediate the negative regulation of miR-210 inhibitor on hypoxic hPASMC proliferation. Cell Biol Int 2015; 39: 113–120.
110. Gou D, Ramchandran R, Peng X, Yao L, Kang K, Sarkar J et al. miR-210 has an antiapoptotic effect in pulmonary artery smooth muscle cells during hypoxia. Am J Physiol Lung Cell Mol Physiol 2012; 303: L682–L691.
111. Grant JS, Morecroft I, Dempsie Y, van Rooij E, MacLean MR, Baker AH. Transient but not genetic loss of miR-451 is protective in the development of pulmonary arterial hypertension. Pulm Circ 2013; 3: 840–850.
112. Sharma S, Umar S, Potus F, Iorga A, Wong G, Meriwether D et al. Apolipoprotein A-I mimetic peptide 4F rescues pulmonary hypertension by inducing microRNA-193-3p. Circulation 2014; 130: 776–785.
113. Shan F, Li J, Huang QY. HIF-1 alpha-induced up-regulation of miR-9 contributes to phenotypic modulation in pulmonary artery smooth muscle cells during hypoxia. J Cell Physiol 2014; 229: 1511–1520.
114. þ channel in arterial smooth muscle cells. J Cell Biochem 2014; 115: 1196–1205.
115. Kang BY, Park KK, Green DE, Bijli KM, Searles CD, Sutliff RL et al. Hypoxia mediates mutual repression between microRNA-27a and PPARγ in the pulmonary vasculature. PLoS ONE 2013; 8: e79503.
116. Kang K, Peng X, Zhang X, Wang Y, Zhang L, Gao L et al. MicroRNA-124 suppresses the transactivation of nuclear factor of activated T cells by targeting multiple genes and inhibits the proliferation of pulmonary artery smooth muscle cells. J Biol Chem 2013; 288: 25414–25427.
117. Li S, Ran Y, Zhang D, Chen J, Zhu D. MicroRNA-138 plays a role in hypoxic pulmonary vascular remodelling by targeting Mst1. Biochem J 2013; 452: 281–291.
118. Jalali S, Ramanathan GK, Parthasarathy PT, Aljubran S, Galam L, Yunus A et al. Mir-206 regulates pulmonary artery smooth muscle cell proliferation and differentiation. PLoS ONE 2012; 7: e46808.
119. Caruso P, Dempsie Y, Stevens HC, McDonald RA, Long L, Lu R et al. A role for miR-145 in pulmonary arterial hypertension: evidence from mouse models and patient samples. Circ Res 2012; 111: 290–300.
120. Guo L, Qiu Z, Wei L, Yu X, Gao X, Jiang S et al. The microRNA-328 regulates hypoxic pulmonary hypertension by targeting at insulin growth factor 1 receptor and L-type calcium channel-α1C. Hypertension 2012; 59: 1006–1013.
121. Courboulin A, Paulin R, Giguère NJ, Saksouk N, Perreault T, Meloche J et al. Role for miR-204 in human pulmonary arterial hypertension. J Exp Med 2011; 208: 535–548.